Abstract Purpose: Early identification of esophageal cancer patients who are responding or resistant to combined chemoradiotherapy may lead to individualized therapeutic approaches and improved clinical outcomes. We assessed the ability of 3 ¶-deoxy-3 ¶- Conclusions: FLT-PET is suitable and more specific than FDG-PET for depicting early reductions in tumor proliferation that precede tumor size changes after chemoradiotherapy.
F]FLT uptake and histologic Ki-67 distribution in preliminary studies. Conclusions: FLT-PET is suitable and more specific than FDG-PET for depicting early reductions in tumor proliferation that precede tumor size changes after chemoradiotherapy.
Esophageal cancer is one of the most lethal human malignancies. Achievement of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer patients has been shown to be associated with improved clinical outcomes (1 -4) . Methods to reliably evaluate and predict the proportion of residual cancer in the esophagus after chemoradiotherapy, however, are currently lacking. The ability to predict which patients will respond to chemoradiotherapy or develop resistance to it before surgery would be invaluable for individualizing therapeutic approaches and avoiding overtreatment and undertreatment. Therefore, the need for a noninvasive tool that accurately predicts response early during the course of preoperative therapy is widely acknowledged.
Conventional anatomic imaging modalities, such as computed tomography and endoscopic ultrasonography, depict cancer response as changes in tumor size and composition, which may occur only after weeks or months following therapy, and are not ideally suitable for early prediction of response in esophageal cancer. Computed tomography is inaccurate and endoscopic ultrasonography is not always feasible in this setting (5) . Positron emission tomography (PET), with the glucose analogue [ 18 F]fluorodeoxyglucose (FDG), addresses these inherent limitations in anatomic imaging, but may be limited in distinguishing proliferating tumor cells from inflammatory tissue (6 -8) . Other radiolabeled molecular markers may improve the specificity and accuracy of early assessment of treatment response.
Because deregulated proliferation is one of the hallmarks of cancer and a high tumor proliferative rate is associated with aggressive biological behavior and poor response to therapy (9, 10) , imaging the proliferative state of cancer cells is of great interest. Recently, 3 ¶-deoxy-3 ¶- 18 F-fluorothymidine ([ 18 F]FLT), a pyrimidine nucleoside analogue, has been validated in several in vitro and in vivo studies as a promising PET radiopharmaceutical for imaging proliferation and monitoring tumor response (11 -19) . The basis of FLT-PET as a surrogate measure of cancer cell proliferation is dependent on the monophosphorylation of FLT by the thymidine kinase 1 (TK1) enzyme, which results in intracellular trapping of FLT (20) . TK1 is virtually absent in quiescent cells but differentially expressed in the late G 1 and S phases of the cell cycle (21, 22) .
Although FLT-PET has been used to assess proliferation and response to therapy (11, 12, 15 -19) , no study to date has examined FLT-PET for monitoring response to chemotherapy in combination with radiation. We hypothesize that FLT-PET depicts early changes in the proliferative state of esophageal cancer after chemoradiotherapy. To test this hypothesis, we developed experimental in vitro and murine models of esophageal cancer and used a treatment regimen consisting of docetaxel, a semisynthetic taxane (23), and irradiation. Docetaxel in combination with irradiation has been investigated in preclinical studies (23 -28) and used in the clinic to produce an f25% pathologic complete response rate in esophageal cancer (29 -31) . The main objective of this study is to determine whether FLT-PET is suitable and more specific than FDG-PET as a surrogate marker of chemoradioresponse for depicting early reductions in tumor proliferation that precede tumor size changes. 
Materials and Methods

Radiopharmaceuticals
-thymine precursor as previously described (32) . Analytic HPLC showed the product to be >99% radiochemically pure. Radiochemical yield was 7%, and specific activity was estimated to be >2 Ci/Amol. Cells and cell culture. SEG-1 cells, derived from a human Barrett'sassociated adenocarcinoma of the distal esophagus (33), were maintained and grown in DMEM/F12 culture medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% glutamine. Cultures were kept in a humidified 5% CO 2 incubator at 37jC. For cell cycle analysis and radiotracer uptake experiments, 1 Â 10 6 cells were seeded onto 60-mm culture dishes, and 5 Â 10 5 cells were seeded onto six-well plates, respectively.
In vitro treatment with chemoradiation. A single dose of 10 nmol/L docetaxel (Fluka, Sigma Chemical Co., St. Louis, MO) was added to the culture medium. Twenty-four hours after docetaxel treatment, the cells were irradiated with a single dose of 8 Gy using a 137 Cs source (3.7 Gy/min). All control wells were treated with PBS. The concentration of docetaxel and dose of radiation were chosen based on previously published work by Dunne et al. (24) and preliminary data demonstrating cytostatic doses of docetaxel and radiation (data not shown).
In vitro uptake of radiotracers. Cellular uptake of radiotracers was determined according to methods previously described (34) with some modifications. At 0, 4, 12, and 24 hours after docetaxel treatment and 4, 12, 24, and 48 hours after irradiation, 0. were incubated with the radiotracers as described for the treated cells. After incubation, the medium was rapidly removed and rinsed with cold PBS. The cells were harvested by gentle scraping, centrifuged, and weighed and assayed for radioactivity after removal of excess supernatant. The cell pellets and the media samples were solubilized with Soluene 350 and mixed with a liquid scintillation cocktail (Ultima Gold, Packard, Meridian, CT). Radioactivity was measured using a liquid scintillation counter (Tri-Carb 2100TR, Packard) and expressed as dpm. Radiotracer uptake was expressed as cell-to-media ratio: (dpm/g cell) / (dpm/mL medium). Experiments were done and repeated in triplicate.
Cell cycle analysis. At various time points (0, 4, and 24 hours after docetaxel treatment and 24 hours after irradiation), cells were harvested by trypsinization, resuspended in growth medium, resuspended in 2 mL PBS, and fixed by the addition of ice-cold 95% ethanol to 60% while being vortexed. Cells were stored in ethanol overnight at À20jC before staining, then washed and resuspended in PBS containing 10 Ag/mL propidium iodide and 250 Ag/mL RNase A. Cells were incubated at 37jC for 15 minutes before flow cytometric analysis using a Coulter EPICS Profile instrument (Beckman Coulter, Inc., Fullerton, CA). Cell cycle distributions were determined from histograms using Multicycle (Phoenix Flow Systems, San Diego, CA).
Animal tumor model. Male Swiss nu/nu mice from our own specific pathogen-free mouse colony were used at an age of 5 months. Mice were housed three to five per cage; fed sterilized, pelleted food (Agway, Inc., Syracuse, NY), and sterile water ad libitum; and exposed to a 12-hour light/dark cycle. The experimental protocol was approved by the Institutional Animal Care and Use Committee. Mice were maintained in a fully accredited animal facility (American Association for Accreditation of Laboratory Animal Care) and in accordance with present regulations and standards of the U.S. Department of Health and Human Services. Solitary SEG-1 tumor xenografts were generated in the right hind limbs of the mice by 10 AL i.m. injection of a single-cell suspension of 1 Â 10 6 tumor cells. After tumors had grown to a mean diameter of 8 mm as measured in three orthogonal diameters with Vernier calipers, mice were randomized to treatment versus control groups. Mice were treated with either docetaxel alone, radiation alone, docetaxel followed by radiation, or PBS (n = 8).
Chemoradiation treatment of xenografts. Mice were treated with docetaxel and radiation as described previously (26) . Tumors were locally irradiated 24 hours after docetaxel treatment (33 mg/kg i.v. via tail vein) with a single dose of 15 Gy using a small animal 137 Cs irradiator. Irradiations were given under ambient air breathing conditions at a dose rate of 5.4 Gy/min. During irradiation, the mice were mechanically immobilized (unanesthetized) on a jig, and the tumor was centered in a 3-cm-diameter circular field. Tumor response to treatment was assessed by tumor growth delay as previously described (26) .
Immunohistochemical staining for proliferation. Excised tumors were fixed in 10% neutral buffered formalin and embedded in paraffin blocks, from which 4-Am sections were cut for H&E and immunohistochemical staining. A section from each specimen was labeled using the monoclonal antibody B56 (BD PharMingen, San Diego, CA), which recognizes the nuclear proliferation associated Ki-67 antigen (35) , and visualized using the Vectastain ABC kit with 3,3 ¶-diaminobenzidine (Vector Laboratories, CA) and hematoxylin counterstain. Ki-67 expression was quantified according to previously described methods with modifications (36) . The fraction of Ki-67-labeled tumor cells was assessed by microscopic examination of stained sections at Â400 magnification. Five fields of nonnecrotic areas were randomly selected in each specimen, and in each field, the numbers of Ki-67-labeled cells were recorded as numbers per 200 to 300 nuclei scored and expressed as labeling index percentages (LI F]FDG imaging sessions. The acquired list data was then histogrammed into a single frame using Fourier rebinning, and the images were reconstructed into a 128 Â 128 Â 63 (0.72 Â 0.72 Â 1.3 mm) matrix using ordered subset expectation maximization. All corrections for attenuation, scatter, dead time, and randoms were applied to generate quantifiable images. Regions of interest were then drawn over the tumor and muscle tissue without including their respective visible boundaries and an average value within the regions of interest was generated. A ratio of tumor-to-muscle (T/M) was calculated to eliminate the dependency on the injected activity. This ratio was evaluated before and after treatment as an indicator of treatment response.
Imaging-histologic correlation with autoradiography. Autoradiograraphy was done only on tumors from mice injected with [ Statistical analysis. Statistical comparisons between controls and treated groups were calculated using the two-sided Student's t test for changes in tumor size and LI Ki-67 . Single-factor ANOVA was used to compare in vitro and in vivo radiotracer uptake before and after treatment. Correlations between histologic and radiotracer uptake findings were tested using linear regression analysis. All quantitative data were reported as mean F SE unless otherwise specified. P < 0.05 was considered to be statistically significant.
Results
Cellular uptake of radiotracers in vitro after chemoradiotherapy. Figure 1 The uptake subsequently declined rapidly to 2.92 F 0.16 (À26%, P = 0.005) at 24 hours and continued to steadily decrease to 0.68 F 0.06 at 72 hours after docetaxel treatment (24 hours after irradiation) compared with baseline uptake (À83%, P = 0.006).
The ]FDG uptake declined by 31% compared with baseline (P = 0.01) at 36 hours and continued to gradually decrease an additional 10% compared with baseline (P = 0.004) at 72 hours after docetaxel (48 hours after irradiation).
Cell cycle analysis. To examine the effects of docetaxel and irradiation on cell cycle distribution, flow cytometric analysis was done on SEG-1 cells in vitro after treatment (Fig. 1C) Effect of chemoradiotherapy on xenograft tumor size and proliferation. The antitumor effect of docetaxel and radiation on SEG-1 tumor-bearing mice, assessed by tumor growth delay, is shown in Fig. 2A . Although the untreated group tumors continued to increase in size during the first few days after treatment, the tumors in the docetaxel plus irradiation group maintained stable sizes: 0 days (pretreatment), 7.98 F 0.05 mm; 2 days, 8.12 F 0.08 mm; and 4 days, 7.96 F 0.12 mm. A significant reduction in tumor size was observed at 8 days with a maximal decline at 10 days in this treatment group (P = 0.03).
Because there was no significant change in tumor size in the first 4 days after chemoradiotherapy, we stained and quantified histologic sections of SEG-1 tumors for Ki-67 to assess temporal changes in tumor proliferation after treatment during this time period (Fig. 2B-C) . The baseline LI Ki-67 of pretreatment SEG-1 tumors was high at 92.10 F 1.49%. A statistically significant decrease in tumor proliferation by 11% (P = 0.02) was observed as early as 4 hours after treatment compared with pretreatment LI Ki-67 (data not shown). LI in treated tumors continued to decline rapidly by 87% to 12.43 F 1.05% at 96 hours compared with untreated tumors (P < 0.001).
Ex (Fig. 3) . Absolute tumor uptake of [ 3 H]FLT after treatment was characterized by a statistically significant steep decline compared with pretreatment tumors at 1 day (À72%, P = 0.006), followed by a continued stable decline (2 days, À75%; 4 days, À76%; P < 0.005). The decrease in [ 3 H]FDG tumor uptake after treatment, however, was less pronounced, reaching a statistically insignificant decrease by 15% at 4 days compared with pretreatment tumors. Figure 3A To further investigate the specificity of FLT and FDG uptake for changes in tumor proliferation after chemoradiotherapy, we compared the radiotracer uptake for individual tumors with the corresponding changes in LI Ki-67 within the same tumors ( Fig. 3C-D) . A strongly positive correlation was found between [ 3 H]FLT uptake in SEG-1 tumors and LI Ki-67 (r = 0.89, P < 0.001). [ 3 H]FDG tumor uptake, however, weakly correlated with LI Ki-67 (r = 0.39, P = 0.08).
Micro-PET studies. Figure 4 shows representative coronal and transverse micro-PET images of SEG-1 tumor-bearing mice Imaging-histologic spatial correlation. Figure 5 shows preliminary data that the spatial distribution of 
Discussion
This is the first study to provide preclinical evidence that FLT-PET accurately depicts early changes in tumor proliferation after chemoradiotherapy that precede tumor volume changes in in vitro and in vivo models of esophageal cancer. Our findings suggest that FLT-PET may be useful as a noninvasive imaging modality to assess early response to chemoradiotherapy in esophageal cancer. The ability of FLT-PET to detect response to chemoradiotherapy within days of treatment (after 48 hours) may allow physicians to overcome the inherent limitations imposed by conventional anatomic imaging and individualize therapeutic approaches according to whether tumors are chemoradioresponsive or chemoradioresistant. Specifically, the early identification of chemoradiotherapy responders and nonresponders would assist in avoiding unnecessary, highly morbid surgical procedures for responders (i.e., esophagectomy) and discontinuing ineffective neoadjuvant treatment regimens and instituting alternative therapies for nonresponders, thereby reducing delays in clinical management and potentially improving clinical outcomes in esophageal cancer.
The combination of docetaxel and radiation resulted in significant reduction of FLT uptake in tumors, which was depicted in our in vitro and ex vivo uptake and micro-PET imaging studies. When normalized to muscle tissue, FLT uptake in tumors in our ex vivo study decreased in a stepwise fashion with a sharp decline as early as 1 day after treatment, followed by a stable decline over the next 3 days. [ 18 F]FLT micro-PET showed the feasibility of imaging these changes. Importantly, these reductions in FLT tumor uptake were not secondary to decreases in tumor volume, because early reduction in FLT uptake occurred during the first few days of cytostatic tumor growth. Similar findings were reported in other FLT-PET preclinical studies that used different anticancer therapies, including chemotherapy (15, 16, 19) and radiation (12, 17) . Our data lend further support to the literature showing the ability of FLT-PET to detect therapeutic alterations in tumor biology before changes in tumor size are clinically detectable. It is not clear at this point whether FLT uptake after chemoradiotherapy differs from treatment with chemotherapy alone or radiation alone. The intent of the growth delay studies was to show the superior efficacy of combined docetaxel and radiation in our tumor model rather than to compare FLT uptake changes between the different treatment regimens. Future studies examining these differences would be interesting.
We validated the specificity of FLT-PET for depicting changes in tumor proliferation by demonstrating a significantly positive correlation between FLT tumor uptake reduction and conventional assessments of cellular proliferation. The dynamics of this reduction in vitro closely resembles the changes in [ 3 H]Thd tumor uptake after treatment, which is consistent with other in vitro comparative uptake studies of [
H]FLT and [
3 H]Thd (14, 20) . Our data, however, are the first to establish that this correlation with Thd remains intact after anticancer treatment in vitro. The altered patterns of cell cycle distribution of SEG-1 cells after docetaxel (i.e., G 2 -M cell cycle arrest) were also similar to findings in other published reports using taxanes (24, 25, 37) . The reduction in G 1 -S phase cells after docetaxel further supports the rationale for using FLT-PET to assess proliferative response after chemoradiotherapy, because cellular FLT uptake is dependent on late G 1 -S phase specific expression of TK1 (21, 22) .
It is interesting to note the initial increase in [ 3 H]FLT and [ 3 H]Thd uptake immediately after docetaxel that precedes their decline (Fig. 1) . The cell cycle data also show a similar increase in S-phase cells, which suggests that this finding may be explained by an accumulation of S-phase cells as cells progress through the cell cycle beyond the G 2 -M into S phase. This in vitro finding is in contrast to the early decreases in [
3 H]FLT and Ki-67 observed in tumor xenografts after chemoradiotherapy. It must be pointed out, however, that the early decreases in proliferation in vivo are observed after the administration of both docetaxel and irradiation 24 hours later. Although we did not study the proliferative status of xenografts immediately after docetaxel alone, it is possible that a transient, initial increase in Ki-67 would also have been observed similar to in vitro studies.
A unique finding in our study was the spatial correlation between FLT uptake and Ki-67 expression distribution on autoradiography. Previous studies have shown the strong correlation between overall FLT tumor uptake and histologic assessment of cellular proliferation (Table 1) . Although preliminary, our finding is the first evidence that this correlation also exists spatially for FLT-PET with reasonably high fidelity, adding to the robustness of FLT as an imaging surrogate of tumor proliferation. Furthermore, imaginghistologic correlation also buttresses the rationale and feasibility of delivering escalated doses of radiation to regions of high tumor proliferative activity in the clinical setting through conformal image-guided radiation therapy. A recent small pilot study that staged 10 (38) . The small number of patients and potential for sampling error in biopsy specimens in that study may have contributed to the discrepancy from our findings. Only a study involving more patients and tightly controlled tumor sampling protocols could resolve this discrepancy.
Although 18 F]FDG in RIF-1 tumor-bearing mice after cisplatin treatment (r = 0.89 versus r = 0.55, respectively). Similarly, we showed early decreases in FLT tumor uptake that were more pronounced and specific for tumor proliferation than those of FDG. Furthermore, when normalizing FLT uptake to background (muscle) uptake as was done in other studies (12, 18, 19) , FLT displayed a much greater T/M signal contrast than FDG. Our data provide additional evidence for the assertion that imaging tumor proliferation with [ 18 F]FLT is more suitable for monitoring treatment response than imaging tumor glucose metabolism.
It should be noted that in our tumor models, the baseline absolute [ 3 H]FDG tumor uptake in our in vitro and ex vivo studies was low compared with absolute [ It is also possible that, similar to the low baseline [ 18 F]FDG uptake observed in the Waldherr et al. study (19) , SEG-1 tumor cells in our study had low FDG uptake as well. However, this is unlikely considering the relatively high tumor uptake of [ 18 F]FDG in our micro-PET imaging study.
In conclusion, this present study showed that FLT-PET is suitable for depicting early reductions in tumor proliferation (48 hours after chemoradiotherapy) in preclinical models of esophageal cancer after chemoradiotherapy before changes in tumor size are evident. We conclude that FLT-PET is superior to FDG-PET as a noninvasive imaging tool to assess early tumor proliferative responses to chemoradiotherapy. Additional studies are ongoing to further determine whether FLT-PET can distinguish between varying degrees of treatment response and predict for pathologic complete response as well as detect early biological changes during the regrowth phase after ineffective Research.
on May 4, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from therapy. Imaging-pathologic studies in patients with esophageal cancer are also under way to validate the sensitivity and specificity of FLT-PET in patients receiving chemoradiotherapy. If these endeavors are successful, they may allow physicians to tailor chemoradiotherapy regimens during the early phase of a treatment course and avoid ineffective and morbid therapies.
